Holen Sie sich die Stockscreener-App
11.01
3.25%
-0.37
Handel nachbörslich:
11.03
0.02
+0.18%
Schlusskurs vom Vortag:
$11.38
Offen:
$11.25
24-Stunden-Volumen:
324.95K
Relative Volume:
0.54
Marktkapitalisierung:
$235.37M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-2.2242
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
-0.09%
1M Leistung:
+46.02%
6M Leistung:
+115.88%
1J Leistung:
-10.34%
1-Tages-Spanne:
$10.86
$11.55
1-Wochen-Bereich:
$10.86
$12.02
52-Wochen-Spanne:
$4.09
$15.34
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
11.01 | 328.35M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Is Enanta Pharmaceuticals Inc. (9EP) stock bottoming after sell offTrade Performance Summary & Weekly Market Pulse Updates - Trung tâm Dự báo KTTV quốc gia
Deep Track Capital, LP Acquires Significant Stake in Enanta Pharmaceuticals Inc - GuruFocus
Enanta’s Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults - Insider Monkey
What high frequency data says about Enanta Pharmaceuticals Inc.2025 Momentum Check & Smart Money Movement Tracker - newser.com
How to forecast Enanta Pharmaceuticals Inc. trends using time seriesWeekly Stock Analysis & Weekly Top Gainers Trade List - newser.com
Quantitative breakdown of Enanta Pharmaceuticals Inc. recent move2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
How Enanta Pharmaceuticals Inc. stock compares to growth peersTrend Reversal & Low Risk Entry Point Guides - newser.com
Why Enanta Pharmaceuticals Inc. stock is rated strong buyWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
Applying sector rotation models to Enanta Pharmaceuticals Inc.Weekly Stock Summary & Community Consensus Stock Picks - newser.com
How Enanta Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Risk Report & Low Drawdown Trading Techniques - newser.com
Enanta pharmaceuticals prices $65M common stock offering - MSN
Chart based analysis of Enanta Pharmaceuticals Inc. trendsJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Why Enanta Pharmaceuticals Inc. stock is seen as undervalued2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Published on: 2025-10-10 06:04:18 - newser.com
Using economic indicators to assess Enanta Pharmaceuticals Inc. potentialJuly 2025 Technicals & Technical Pattern Alert System - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Enanta Pharmaceuticals' (ENTA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Does Enanta Pharmaceuticals Inc. show high probability of rebound2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Is Enanta Pharmaceuticals Inc a good long term investmentGap Fill Strategies & Individual Stock Tracking Service - earlytimes.in
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development fo - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 - Business Wire
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - FinancialContent
Backtesting results for Enanta Pharmaceuticals Inc. trading strategies2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
What’s next for Enanta Pharmaceuticals Inc. stock priceJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Will Enanta Pharmaceuticals Inc. stock benefit from AI adoptionAnalyst Downgrade & Expert Curated Trade Setups - newser.com
Is Enanta Pharmaceuticals Inc. (9EP) stock a buy during volatile markets2025 Market Sentiment & Fast Entry High Yield Tips - newser.com
What Fibonacci levels say about Enanta Pharmaceuticals Inc. reboundJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attention2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
What’s the recovery path for long term holders of Enanta Pharmaceuticals Inc.Market Sentiment Report & Safe Swing Trade Setups - newser.com
Real time alert setup for Enanta Pharmaceuticals Inc. performanceJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Enanta Pharmaceuticals Inc 9EP stockRisk Management Strategies & Minimal Risk High Reward - earlytimes.in
Foley Hoag Advises Enanta Pharmaceuticals on $74.8 Million Upsized Public Offering - Foley Hoag
Enanta upgraded to buy at Jefferies on promise of RSV antiviral zalicapavir - MSN
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward - Sahm
Is Enanta Pharmaceuticals Inc. stock entering bullish territory2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):